WO2018143357A1 - Procédé d'analyse de substance ayant une haute affinité pour une substance cible - Google Patents

Procédé d'analyse de substance ayant une haute affinité pour une substance cible Download PDF

Info

Publication number
WO2018143357A1
WO2018143357A1 PCT/JP2018/003442 JP2018003442W WO2018143357A1 WO 2018143357 A1 WO2018143357 A1 WO 2018143357A1 JP 2018003442 W JP2018003442 W JP 2018003442W WO 2018143357 A1 WO2018143357 A1 WO 2018143357A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
target substance
sample
candidate
high affinity
Prior art date
Application number
PCT/JP2018/003442
Other languages
English (en)
Japanese (ja)
Inventor
光利 瀬藤
豪 近藤
Original Assignee
国立大学法人浜松医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人浜松医科大学 filed Critical 国立大学法人浜松医科大学
Priority to JP2018566091A priority Critical patent/JPWO2018143357A1/ja
Publication of WO2018143357A1 publication Critical patent/WO2018143357A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G01N27/622—Ion mobility spectrometry
    • G01N27/623—Ion mobility spectrometry combined with mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Definitions

  • the present invention screens a substance having a high affinity with a target substance by using imaging mass spectrometry (Imaging Mass Spectrometry: IMS) using a matrix assisted laser desorption ionization (Matrix Laser Desorption / Ionization: MALDI) method. On how to do.
  • imaging mass spectrometry Imaging Mass Spectrometry: IMS
  • matrix assisted laser desorption ionization Microx Laser Desorption / Ionization: MALDI
  • a method for evaluating the interaction between molecules a method using a combination of affinity purification such as immunoprecipitation and a detection system such as Western blot or mass spectrometry, an imaging technique such as fluorescence resonance energy transfer (FRET).
  • FRET fluorescence resonance energy transfer
  • spectrum analysis such as surface plasmon resonance analysis, calorimetric change analysis, high magnetic field nuclear magnetic resonance (NMR), or the like.
  • a method that does not use a probe for detection for example, a method in which a binding molecule for a target substance is detected by liquid chromatography mass spectrometry or the like is generally purified by a method such as immunoprecipitation as a pretreatment.
  • the detectable molecules are limited.
  • a detection system capable of non-target analysis is necessary when conducting research on binding molecules.
  • the three-dimensional structure may change from that in the living body depending on the purification operation or in vitro environment, and trace molecules that exist only in limited parts of the living body can be recovered in the first place. There are also problems such as difficulty.
  • MALDI-IMS mass microscopy
  • a sample to be analyzed such as a tissue slice
  • matrix low-molecular compound
  • Is irradiated with laser light and an image is reconstructed based on the information of ions detected at each point of the two-dimensional coordinates.
  • the tissue section is directly analyzed by two-dimensional laser scanning, the biomolecule on the tissue sample can be ionized while maintaining its position information.
  • the ionized biomolecule is analyzed by a time-of-flight mass spectrometer and identified according to the mass to charge ratio.
  • the distribution of biomolecules on the tissue sample can be imaged by the relative value of the signal intensity between the measurement points.
  • a compound suitable for ionization of biomolecules has been used empirically.
  • an ion-dissociable substance having a molecular weight of 50 or more and less than 300 such as 3,5-methoxy-4-hydroxycinnamic acid and 9-aminoacridine (9AA) is used, and a matrix ionized with biomolecules on a tissue sample
  • the molecules are desorbed and fly from the tissue sample in a bound state, and are separated and identified for each mass-to-charge ratio (m / z) by the analyzer in MALDI-IMS.
  • Patent Document 1 discloses a method for evaluating the therapeutic effect of a candidate compound for a breast cancer therapeutic agent using MALDI-IMS.
  • a large amount of phosphatidylcholine (PC) of a specific molecular species is present in breast tissue due to abnormal lipid metabolism in breast cancer
  • the molecule of phosphatidylcholine in the breast tissue of a subject administered with a candidate compound The abundance ratio of the species is measured by MALDI-IMS, and when the abundance ratio of molecular species present in a large amount in breast cancer patients is low, the candidate compound is evaluated to be effective as a breast cancer therapeutic agent.
  • this method involves directly administering a candidate compound to a subject and comparing before and after exhibiting an anticancer effect through metabolism, so the types of candidate substances that can be used for screening are naturally limited. There was a limit to the efficiency of screening.
  • conventionally, no method has been found to measure the affinity involving a substance in a living body as well as the above-described intermolecular interaction using MALDI-IMS.
  • An object of the present invention is to provide a method for screening a substance having high affinity with a target substance using MALDI-IMS.
  • the present invention provides a method for screening a substance having a high affinity with the following target substance.
  • [1] preparing a measurement sample in which a target substance and a sample containing a candidate substance are brought into contact; Performing an imaging mass spectrometry method using the MALDI method with the target substance as a matrix on the measurement sample, and identifying ionized molecules; Selecting the identified molecule as a substance having high affinity with the target substance; A method for screening a substance having high affinity with a target substance.
  • the step of preparing the measurement sample is as follows: Contacting a test sample containing a candidate substance with a target substance; Drying the contacted sample and the target substance in a contact state to obtain a measurement sample, and The identification step performs a spectrum scanning step of obtaining an ionized molecule spectrum by performing imaging mass spectrometry using MALDI method on the measurement sample, Identifying a peak substance from the spectrum, The method of [1].
  • the candidate substance is a phospholipid.
  • [5] The samples according to [1] to [4], wherein the sample containing the candidate substance is a tissue section, and the measurement sample is obtained by attaching the target substance to the surface of the sample containing the candidate substance. Either way.
  • the wavelength of a laser used for imaging mass spectrometry using the MALDI method is 200 to 400 nm, The method according to any one of [1] to [5], wherein the target substance is a compound having a molecular weight of 300 to 10,000 containing an aromatic ring and / or a heterocyclic ring.
  • control substance is 3,5-methoxy-4-hydroxycinnamic acid, ⁇ -cyano-4-hydroxycinnamic acid, trans-4-hydroxy-3-methoxycinnamic acid, 2,5-dihydroxy
  • the target substance is a phospholipid.
  • the sample containing the target substance is a tissue section, and the measurement sample is obtained by attaching the candidate substance to the surface of the sample containing the target substance. That way.
  • the wavelength of a laser used for imaging mass spectrometry using the MALDI method is 200 to 400 nm, and the candidate substance is a compound having a molecular weight of 300 to 10,000 including an aromatic ring and / or a heterocyclic ring. 9] to any one of [12].
  • a method for designing a medicine comprising a screening step for a substance having a high affinity with the target substance of any one of [9] to [13], and a candidate substance selected by the screening process as an active ingredient .
  • a method for producing a medicine comprising a screening step of a substance having a high affinity with the target substance of any one of [9] to [13], and containing a candidate substance selected by the screening process as an active ingredient .
  • the method for screening candidate substances having high affinity with the target substance according to the present invention By the method for screening candidate substances having high affinity with the target substance according to the present invention, candidate substances having strong affinity for the target substance can be comprehensively selected without limiting the molecules to be analyzed. For this reason, the method is particularly suitable for selecting a substance (biomolecule) having high affinity for a target substance of interest from a sample containing various biomolecules such as a biological sample such as a tissue slice. In addition, the method for screening candidate substances having high affinity with the target substance (biomolecule) according to the present invention comprehensively selects candidate substances having strong affinity for the target substance without limiting the molecules to be analyzed. can do. For this reason, this method is particularly suitable for selecting substances exhibiting high affinity for the target substance (biomolecule) of interest from various candidate compounds that can have a pharmacological action.
  • Example 1 it is the mass spectrum acquired by MALDI-IMS performed with respect to the mouse
  • Example 1 is the molecular distribution image figure which built two-dimensionally the spectrum data acquired by MALDI-IMS according to ionic strength.
  • Example 1 it is the result of the multistage MS analysis with respect to the ion peak characteristic of clozapine.
  • Example 1 it is the mass spectrum acquired by MALDI-IMS performed with respect to PIP2 spotted on the electroconductive slide glass.
  • Example 1 it is the figure which showed the result of the liposome binding experiment. It is process drawing which shows other embodiment of this invention.
  • the method for screening a substance having high affinity with the target substance according to the present invention is a screening method using MALDI-IMS.
  • the screening method includes a step of preparing a measurement sample in which a target substance and a sample containing a candidate substance (test sample) are brought into contact, and the target for the measurement sample.
  • MALDI-IMS using a substance as a matrix to identify an ionized molecule, and selecting the identified molecule as a substance having a high affinity for the target substance.
  • a substance having a high affinity with the target substance in the sample is ionized. Therefore, by identifying this ionized molecule and selecting it as a substance with high affinity for the target substance, it is possible to comprehensively select substances that have a strong affinity for the target substance contained in the sample. it can.
  • the step of preparing the measurement sample includes the step of bringing the test sample and the prepared target substance into contact with each other, drying the contacted sample and the target substance in a contact state, and measuring the sample. And a drying step as a sample.
  • the identification step includes a spectrum scanning step for obtaining a spectrum of ionized molecules by performing imaging mass spectrometry using a MALDI method on the measurement sample, and an identification step for identifying a peak substance from the spectrum. Contains.
  • the screening method of the present invention will be described in detail with reference to FIG.
  • it demonstrates as an example which searches for a candidate substance with high affinity in the living body with respect to a known target substance.
  • “high affinity” is used synonymously with “having affinity”.
  • the test sample preparation process and the target substance preparation process will be described.
  • FIG. 1 is a process diagram showing a screening method of the present invention.
  • MALDI-IMS imaging mass spectrometry method using a MALDI method.
  • spectrum scanning step 600 and peak substance identifying step 900 are included.
  • the test sample creation step 100 is a test sample creation step for creating a test sample containing a candidate substance.
  • a candidate substance that is, a substance expected to be a substance having a high affinity with a target substance described later is not particularly limited as long as it is a substance ionized by MALDI-IMS.
  • examples include organic compounds (also referred to as biomolecules) contained in living bodies such as sugars, nucleic acids, proteins, lipids, organic acids, and vitamins.
  • identification of molecules ionized in IMS is easier, so that the substance has a relatively small molecular weight, such as phospholipid, peptide, oligonucleotide, vitamin, and the like, and is relatively easy to identify in IMS.
  • the candidate substance is preferably a phospholipid or an organic acid, and more preferably a phospholipid, from the point that the analysis results by MALDI-IMS are substantial.
  • phospholipids include phosphatidylinositol (PI), phosphatidylinositol monophosphate (PIP, PIP1), phosphatidylinositol diphosphate (PIP2) and phosphatidylinositol triphosphate (PIP3), phosphatidylcholine (PC), phosphatidylethanolamine
  • glycerophospholipids such as (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), and diphosphatidylglycerol (cardiolipin), and sphingophospholipids such as sphingomyelin.
  • the test sample is not particularly limited as long as it contains a candidate substance.
  • the test sample may be a sample collected from a living body, or an artificially prepared sample.
  • biological samples include tissue fragments collected from living organisms, blood, lymph, bone marrow, ascites, exudates, amniotic fluid, sputum, saliva, semen, bile, pancreatic juice, urine, and other body fluids, intestinal lavage fluid, lungs
  • An organ cleaning solution such as a cleaning solution may be used.
  • the artificially prepared sample include purified known substances or a mixture of two or more kinds of purified known substances.
  • tissue piece When using a body fluid, a washing solution, or the like as a test sample, it is also preferable to concentrate and purify candidate substances in advance by centrifugation, chromatography, electrophoresis, or the like.
  • the tissue piece may be used as a lump, or a suspension obtained by homogenizing the tissue piece in an appropriate buffer may be used as a test sample. Collection of tissue pieces and body fluids from a living body, washing solution, centrifugation, chromatography, electrophoresis, homogenization, and the like can be performed by conventional methods.
  • tissue piece collected from a living body is preferable because it is possible to examine the affinity with a target substance in a state in which the environment in the living body is relatively maintained by utilizing the characteristics of IMS.
  • a tissue section in which a tissue piece is thinned is more preferable.
  • the “tissue piece” includes not only a tissue piece itself collected from a living body but also a tissue piece embedded in paraffin and a tissue piece deparaffinized after embedding in paraffin.
  • the “tissue section” means a section of a tissue piece obtained by embedding a tissue piece collected from a living body in addition to a frozen section of a tissue piece collected from a living body, Also included are sections of paraffin tissue pieces.
  • collection recovery of the tissue piece from a biological body, paraffin embedding, and deparaffinization can be performed by a conventional method.
  • the tissue piece collected from the living body may be collected from a healthy living body, or may be collected from a living body having a disease or a disorder. For example, a so-called pathological tissue may be used.
  • the target substance preparation step 200 is a target substance preparation step for preparing a target substance.
  • the target substance is a target substance for screening for a substance (candidate substance) having high affinity with the substance.
  • the target substance is not particularly limited as long as it can function as a matrix in MALDI-IMS.
  • sugars, nucleic acids as well as artificial compounds such as pharmaceuticals and low molecular compounds (chemical libraries, etc.)
  • Organic compounds contained in living bodies such as proteins, lipids, organic acids and vitamins.
  • an organic compound having a molecular weight of 10,000 or less is preferable because it is easily excited by selecting a laser beam having an appropriate wavelength in IMS and is suitable as a matrix.
  • the molecular weight is more than 10,000.
  • the organic compound may be used.
  • the molecular weight of the organic compound is typically 10,000 or less, 8,000 or less, 5,000 or less, 3,000 or less, or 1,000 or less, and 100 or more, 200 or more, 300 or more, 400 or more, or 500 or more.
  • MALDI-IMS differs in the chemical structure of a compound suitable for screening a substance having a high affinity because the excited energy differs depending on the laser wavelength used. Specifically, in the case of MALDI-IMS using a laser that oscillates at a wavelength of 200 to 400 nm, if the compound is an organic compound having an aromatic ring and / or a heterocyclic ring, the energy of the laser is efficiently converted, and Candidate substances (biomolecules) can be ionized together.
  • the solution for suspending or dissolving the target substance is not particularly limited as long as it is a solution that can be suspended or dissolved without chemically altering the target substance.
  • Phosphate buffer, Tris buffer, etc. These can be selected appropriately from various buffers, organic solvents such as alcohols and ketones, or water according to the target substance.
  • alcohols such as methanol and ethanol are preferable because they have little influence on a biological sample or an organic compound contained in the living body and easily volatilize.
  • the contact process 300 mentioned later is vapor deposition, it may remain a powder or paste-like solid.
  • the contact process 300 is a contact process in which the prepared test sample is brought into contact with the prepared target substance.
  • the target substance prepared in the target substance preparation step 200 and the test sample prepared in the test sample preparation step 100 were brought into contact with each other.
  • the measurement sample is not particularly limited as long as the candidate substance in the test sample is in contact with the target substance.
  • the measurement sample is preferably flat so that measurement by IMS is possible.
  • a method for attaching the target substance to the surface of the test sample for example, a method in which a solution in which the target substance is dissolved or suspended in a buffer is sprayed so as to uniformly adhere to the surface of the test substance, the solution is used.
  • the solution examples thereof include a method of applying with a brush or the like, a method of immersing a test sample in the solution, and the like.
  • a mixture obtained by mixing the test sample and the target substance is a thin film such as a PVDF (polyvinylidene fluoride) film or a nitrocellulose film.
  • a sample plotted on a conductive slide glass can be used as a measurement sample.
  • a solution in which a candidate substance is dispersed or dissolved is plotted on a thin film such as a PVDF film or a nitrocellulose film or a conductive slide glass, and the target substance is attached to the surface of this thin film.
  • a thin film such as a PVDF film or a nitrocellulose film or a conductive slide glass
  • the target substance is attached to the surface of this thin film.
  • the test sample is a tissue piece or a tissue section
  • a sample having a target substance attached to these surfaces can be used as a measurement sample.
  • the contact process 300 may be a vapor deposition method such as vacuum deposition.
  • the drying process 500 is a drying process in which the contacted sample and the target substance are dried in a contact state to obtain a measurement sample.
  • the mass spectrometer used for the MALDI-IMS method is maintained in a high vacuum state.
  • volatile components (solvents, etc.) in the solution may be contained, and if it is directly subjected to MALDI-IMS, gas is generated in the apparatus and the degree of vacuum necessary for analysis is maintained. There is a risk of not being able to hit. For this reason, drying is performed for a predetermined time according to the state of the measurement sample. As an example, air drying can be performed for about 1 to 120 minutes.
  • the contact process 400 and the drying process 500 are continuous, and it is desirable to shift to a process while maintaining the state without tilting the sample.
  • a process while maintaining the state without tilting the sample.
  • the drying process 500 may use heating means such as a hot plate or an infrared lamp in order to shorten the time. However, it is necessary to pay attention to the heating temperature so that the test sample is not thermally decomposed and migration of candidate substances in the test sample does not occur. Further, the drying process 500 is not limited to the atmosphere, and may be performed in a vacuum apparatus different from the MALDI-IMS. In this case, even if gas is generated in the drying process 500, it is only necessary to lower the vacuum degree of the vacuum device, and there is an advantage that the MALDI-IMS device is not contaminated.
  • heating means such as a hot plate or an infrared lamp
  • a co-crystal growth step 400 may be provided between the contact step 300 and the drying step 500.
  • the co-crystal growth process 400 is held at a predetermined temperature, a predetermined humidity or a spatial solvent concentration, and a predetermined time so that the co-crystal is formed and grows when the target substance and the candidate substance can form a co-crystal. For example, it is left in a closed space such as a petri dish or a desiccator.
  • MALDI-IMS is performed on the prepared measurement sample, and ionized molecules are identified.
  • Specific processes include a spectrum scan process 600 and a peak substance identification process 800.
  • the spectrum scan step 600 is a step of performing a spectrum scan in a predetermined m / z range by an imaging mass spectrometry method (MALDI-IMS) using the MALDI method.
  • MALDI-IMS imaging mass spectrometry method
  • One example is a scan in the range of mass-to-charge ratio (m / z) from 0 to 3000, and another example is a scan in the range of 500 to 2500 m / z.
  • m / z mass-to-charge ratio
  • a scan with a relatively narrow range including an expected m / z may be used.
  • MALDI-IMS can be implemented by a conventional method.
  • a test sample obtained through the drying process 500 and having a target substance attached to the surface thereof is placed on a glass slide coated with ITO (indium oxide), and this glass slide is placed in an imaging mass spectrometer. Then, the organic compound in the test sample is ionized while maintaining the position information by two-dimensional laser scanning, and a mass spectrum is acquired.
  • ITO indium oxide
  • the step 800 for identifying the peak material is a step for identifying the peak material from a spectrum in a predetermined range obtained from MALDI-IMS. For example, mass spectra acquired using software attached to the apparatus or commercially available software are analyzed, and ionized molecules corresponding to the peaks are identified. For identification of molecules from mass spectra, refer to known databases (eg (http://www.lipidmaps.org/data/structure/LMSDSearch.php)) according to mass-to-charge ratio (m / z) Can be done. In this way, a candidate substance (biomolecule) having a high affinity for the target substance in vivo can be identified. The identified molecule can be confirmed to be able to obtain the same mass spectrum by performing MALDI-IMS in the same manner using the target substance alone.
  • known databases eg (http://www.lipidmaps.org/data/structure/LMSDSearch.php)
  • m / z mass-to-charge ratio
  • the mass spectrum acquired by MALDI-IMS may include a mass spectrum of molecules that are not highly compatible with the target substance but are easily ionized. Therefore, in order to specify a mass spectrum of a substance having a high affinity for the target substance, MALDI-IMS is similarly performed on the same test sample using a substance different from the target substance as a control substance (Steps 100, 200, 300). , 500, 600, and 800), by removing the mass spectrum obtained using the control substance as a matrix as noise, the accuracy of screening can be improved.
  • a step of preparing a control sample for measurement in which a control substance and a sample containing the candidate substance are brought into contact with each other, and MALDI-IMS using the control substance as a matrix for the control sample for measurement are prepared.
  • the control substance is not particularly limited as long as it is a substance other than the target substance.
  • a compound widely used as a matrix in MALDI-IMS can be used because excitation by laser irradiation is easy.
  • the general-purpose compound include 3,5-methoxy-4-hydroxycinnamic acid, ⁇ -cyano-4-hydroxycinnamic acid, trans-4-hydroxy-3-methoxycinnamic acid, and 2,5-dihydroxy. Examples include benzoic acid, 3-hydroxypicolinic acid, 9-aminoacridine (9AA), 2,5-dihydroxyacetophenone, or 1,8-dihydroxy-9,10-dihydroanthracen-9-one.
  • These general-purpose compounds are not drugs, and the peak of mass spectrum obtained by MALDI-IMS can be treated as negative data (noise).
  • a substance having a structure similar to that of the target substance can be used as a control substance.
  • the peak of the mass spectrum obtained by MALDI-IMS can be handled as positive data supporting the peak of the candidate substance obtained for the target substance.
  • the target substance can be specifically identified with the drug in an environment closer to the living body. It is possible to exhaustively search for biomolecules that can bind. In addition, it is possible to confirm from which part of the living tissue the spectrum data obtained by MALDI-IMS is two-dimensionally constructed according to the ion intensity. Information on the localization of a molecule that binds to a drug in a tissue is useful for elucidating the mechanism of action of the drug in vivo.
  • tissue section having a thickness of about 10 ⁇ m at intervals of 5 ⁇ m in length and width.
  • a trace amount of biomolecules present only at a local site can be analyzed without prior purification.
  • the characteristic ion peak can be analyzed in detail by performing a multi-stage MS analysis process 700 (not shown) subsequent to the spectrum scan process 600.
  • the screening method according to the present invention can be a powerful means for exhaustively searching for biomolecules having affinity for pharmaceutical products and candidate compounds.
  • the screening method according to the present invention detects and identifies a substance having a high affinity with a target substance by mass spectrometry, it is not necessary to develop a high-quality probe for each target substance in order to detect an interaction, and it is comprehensive. Exploratory research is possible.
  • a tissue section can be used as a test sample as it is, biomolecules (candidate substances) are held in a state close to the living body, so that it is difficult to maintain the original structure by extraction operation. Suitable for analysis of constituent molecules.
  • screening can be performed more rapidly.
  • Example 1 An example of searching for a biomolecule (candidate substance) showing affinity for a specific drug (target substance) will be described below.
  • biomolecules candidate substances, affinity molecules
  • clozapine target substance
  • a mouse brain section was prepared (test sample preparation step 100).
  • a clozapine (Clz) solution (2 mg / mL) in which clozapine (CAS No. 5786-21-0, molecular weight: 327) was dissolved in methanol was prepared (target substance preparation step 200).
  • target substance preparation step 200 was prepared.
  • the clozapine solution was spray applied to the mouse brain slice by spraying and contacted (contact process 300).
  • FIG. 2 The acquired mass spectrum is shown in FIG.
  • (a) “9AA” is a mass spectrum obtained using 9-aminoacridine
  • FIG. 2 (b) “Clz” is a mass spectrum obtained using clozapine
  • “Olz” is a mass spectrum acquired using olanzapine.
  • FIGS. 2A to 2C common peaks are observed in the vicinity of m / z 888 and 905.
  • FIG. 2B On the other hand, with respect to clozapine, which is an antipsychotic drug, specific peaks not observed elsewhere are observed at m / z 965 and 1045 (FIG. 2B).
  • FIG. 3 shows a molecular distribution image diagram in which the obtained spectrum data is two-dimensionally constructed according to the ionic strength (m / z is four conditions of 885.55, 888.62, 965.52, 1045.48). ).
  • the meanings of the abbreviations “9AA”, “Clz”, and “Olz” are the same as described above.
  • “9AA”, “Clz”, and “Olz” have different molecular distribution images, and the distribution in the mouse brain of molecules with high affinity for clozapine and molecules with high affinity for olanzapine is different.
  • an ion peak characteristic of clozapine that is, an ion peak that is not detected when 9-aminoacridine or olanzapine is used among ion peaks detected when clozapine is used.
  • M / z 965 and 1045 were selected as ion peaks of molecules having high affinity for clozapine.
  • multistage MS process 700 multistage MS process 700
  • FIG. 4 (a) shows only the m / z 965 ion obtained in the process of the spectrum scan process 600, and further decomposes it by giving kinetic energy as multi-stage MS analysis (MS / MS). Is observed.
  • FIG. 4B shows only the m / z 1045 ions obtained in the process of the spectrum scanning process 600, which is further decomposed by giving kinetic energy as multi-stage MS analysis (MS / MS). The spectrum was observed. From the peak m / z of the fragment ions of each decomposed product, the ion of m / z 965 was identified as PIP1, and the ion of m / z 1045 was identified as PIP2.
  • PIP1 and PIP2 could be selected as molecules having high affinity with clozapine.
  • olanzapine showed no affinity with PIP1 and PIP2, suggesting that the difference in pharmacological action between clozapine and olanzapine as an antipsychotic is due to the difference in affinity between PIP1 and PIP2.
  • Phosphatidylinositol 4,5-bisphosphate diC4 (molecular weight 744, Echelon Biosciences Inc. catalog number P-4504), which is a standard substance of PIP2, is used. Used as a test sample. Specifically, mass spectrometry is performed by performing MALDI-IMS in the same manner except that P-4504 spotted on a conductive slide glass is used as a test sample and a methanol solution of clozapine or olanzapine is mixed on the glass. did.
  • FIG. 5A A mass spectrum acquired from a spot mixed with clozapine is shown in FIG. 5A, and a mass spectrum acquired from a spot mixed with olanzapine is shown in FIG. 5B.
  • the meanings of the abbreviations “Clz” and “Olz” are the same as described above.
  • the candidate substance PIP2 selected for the target substance clozapine by the screening method of the present invention showed high affinity that can be said to be specific for the target substance clozapine in the buffer solution. From this, it was proved that the screening method of the present invention is effective in determining the presence or absence of affinity between two substances in vivo.
  • the second screening method of the present invention will be described in detail with reference to FIG.
  • it demonstrates as an example which searches for a candidate substance with high affinity in the living body with respect to the known standard substance (biomolecule) in the living body. Further, the test sample preparation process and the target substance preparation process will be described.
  • FIG. 7 is a process diagram showing a second screening method of the present invention, in which a test sample preparation process 150, a candidate substance preparation process 250, a contact process 300, a drying process 500, and an imaging using a MALDI method are performed.
  • a target substance (m / z) scanning step 650 by mass spectrometry (MALDI-IMS) and a peak intensity measuring step 900 are included.
  • the test sample creation step 150 is a test sample creation step for creating a test sample containing a target substance.
  • the target substance that is, a substance expected to be a substance having a high affinity with a candidate substance described later is not particularly limited as long as it is a substance ionized by MALDI-IMS.
  • examples include organic compounds (also referred to as biomolecules) contained in living bodies such as sugars, nucleic acids, proteins, lipids, organic acids, and vitamins.
  • identification of molecules ionized in IMS is easier, so that the substance has a relatively small molecular weight, such as phospholipid, peptide, oligonucleotide, vitamin, and the like, and is relatively easy to identify in IMS. Is preferred.
  • the candidate substance is preferably a phospholipid or an organic acid, and more preferably a phospholipid, from the point that the analysis results by MALDI-IMS are substantial.
  • phospholipids include phosphatidylinositol (PI), phosphatidylinositol monophosphate (PIP, PIP1), phosphatidylinositol diphosphate (PIP2) and phosphatidylinositol triphosphate (PIP3), phosphatidylcholine (PC), phosphatidylethanolamine
  • glycerophospholipids such as (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), and diphosphatidylglycerol (cardiolipin), and sphingophospholipids such as sphingomyelin.
  • the test sample is not particularly limited as long as it contains the target substance.
  • the test sample may be a sample collected from a living body, or an artificially prepared sample.
  • biological samples include tissue fragments collected from living organisms, blood, lymph, bone marrow, ascites, exudates, amniotic fluid, sputum, saliva, semen, bile, pancreatic juice, urine, and other body fluids, intestinal lavage fluid, lungs
  • An organ cleaning solution such as a cleaning solution may be used.
  • the artificially prepared sample include purified known substances or a mixture of two or more kinds of purified known substances.
  • tissue piece When using a body fluid, a washing solution, or the like as a test sample, it is also preferable to concentrate and purify candidate substances in advance by centrifugation, chromatography, electrophoresis, or the like.
  • the tissue piece may be used as a lump, or a suspension obtained by homogenizing the tissue piece in an appropriate buffer may be used as a test sample. Collection of tissue pieces and body fluids from a living body, washing solution, centrifugation, chromatography, electrophoresis, homogenization, and the like can be performed by conventional methods.
  • tissue piece includes not only a tissue piece itself collected from a living body but also a tissue piece embedded in paraffin and a tissue piece deparaffinized after embedding in paraffin.
  • the “tissue section” means a section of a tissue piece obtained by embedding a tissue piece collected from a living body in addition to a frozen section of a tissue piece collected from a living body, Also included are sections of paraffin tissue pieces.
  • collection recovery of the tissue piece from a biological body, paraffin embedding, and deparaffinization can be performed by a conventional method.
  • the tissue piece collected from the living body may be collected from a healthy living body, or may be collected from a living body having a disease or a disorder. For example, a so-called pathological tissue may be used.
  • the candidate substance preparation step 250 is a candidate substance preparation step for preparing a candidate substance.
  • the candidate substance is a substance intended for screening a substance having a high affinity for the target substance.
  • Candidate substances are not particularly limited as long as they can function as a matrix in MALDI-IMS.
  • artificial substances such as pharmaceuticals and low-molecular compounds (chemical libraries, etc.), sugars, nucleic acids, etc. , Organic compounds contained in living bodies such as proteins, lipids, organic acids and vitamins.
  • an organic compound having a molecular weight of 10,000 or less is preferable because it is easily excited by selecting a laser beam having an appropriate wavelength in IMS and is suitable as a matrix.
  • the molecular weight is more than 10,000.
  • the organic compound may be used.
  • the molecular weight of the organic compound is typically 10,000 or less, 8,000 or less, 5,000 or less, 3,000 or less, or 1,000 or less, and 100 or more, 200 or more, 300 or more, 400 or more, or 500 or more.
  • MALDI-IMS differs in the chemical structure of a compound suitable for screening a substance having a high affinity because the excited energy differs depending on the laser wavelength used. Specifically, in the case of MALDI-IMS using a laser that oscillates at a wavelength of 200 to 400 nm, if the compound is an organic compound having at least one aromatic ring and / or heterocyclic ring, the energy of the laser is efficiently converted. Both the compound and the target substance (biomolecule) can be ionized.
  • the solution for suspending or dissolving the candidate substance is not particularly limited as long as it is a solution that can suspend or dissolve the candidate substance without chemically altering the candidate substance.
  • Phosphate buffer, Tris buffer, etc. These can be selected appropriately from various buffers, organic solvents such as alcohols and ketones, or water according to the target substance.
  • alcohols such as methanol and ethanol are preferable because they have little influence on a biological sample or an organic compound contained in the living body and easily volatilize.
  • the contact process 300 mentioned later is vapor deposition, it may remain a powder or paste-like solid.
  • the contact process 300 is a contact process in which the prepared test sample is brought into contact with the prepared target substance, and is the same as the contact process 300 described in the first screening method of the present invention.
  • the drying process 500 is a drying process in which the contacted sample and the target substance are dried in a contact state to obtain a measurement sample, which is the same as the drying process 500 described in the first screening method of the present invention. It is.
  • co-crystal growth process 400 (not shown) is the same as the co-crystal growth process 400 described in the first screening method of the present invention.
  • MALDI-IMS is performed on the prepared measurement sample, and ionized molecules are identified.
  • Specific steps include a target substance (m / z) scanning step 650 and a step 900 of measuring peak intensity.
  • the target substance (m / z) scanning step 650 is a step of scanning m / z corresponding to the target substance (biomolecule) by imaging mass spectrometry (MALDI-IMS) using the MALDI method.
  • MALDI-IMS imaging mass spectrometry
  • m / z 1045 or a peripheral region including m / z 1045 (for example, a range within ⁇ 5% with respect to the center m / z) Scan about can be implemented by a conventional method.
  • a test sample obtained by passing through the drying step 500 and having a target substance attached to the surface thereof is placed on a glass slide coated with ITO (indium oxide), and the glass slide is connected to a MALDI-IMS imaging mass spectrometer.
  • the organic compound in the test sample is ionized while maintaining the position information by two-dimensional laser scanning, and a mass spectrum is acquired.
  • the step 900 of measuring the peak intensity is to measure the peak intensity at the corresponding m / z of the target substance (biomolecule), and to quantify it if necessary.
  • This measurement process 900 includes a process of determining the presence or absence of a peak.
  • a first method of determination if there is a peak at m / z 1045, there is a peak if there is a significant difference in peak intensity compared to the noise area around the peak (for example, m / z 1200) It is determined.
  • the peak intensity is compared with the peak at m / z 1045 of the reference substance spectrum (negative data) such as 9AA described above.
  • the peak intensity is digitized and stored in a memory or the like, and a peak value at m / z 1045 for a plurality of candidate substances. By comparing with the above, the peak with the largest peak value is determined as having a peak (or peak maximum).
  • a section of tissue such as a pathological tissue or a disease model mouse is used as a test sample
  • a biomolecule related to a disease is used as a target substance
  • a compound that can be expected to have a pharmacological effect is used as a candidate substance.
  • candidate drugs that can specifically bind to the biomolecule in an environment closer to the living body can be exhaustively searched.
  • Information on the localization of a molecule that binds to a drug in a tissue is useful for confirming the mechanism of action of the drug in vivo, and information on side effects can be obtained from the distribution state in a normal tissue.
  • a trace amount of biomolecules present only at a local site can be analyzed without prior purification.
  • the characteristic ion peak can be structurally analyzed by performing a multi-stage MS analysis process 700 (not shown) following the spectrum scan process 600. For this reason, the screening method according to the present invention can be a powerful means for comprehensively searching for drugs and candidate compounds having affinity for biomolecules.
  • biomolecules may be involved in the disease independently or in cooperation with each other.
  • target substances biomolecules
  • candidate substances compounds that can be expected to have a pharmacological effect
  • a drug can be designed using the selected candidate substance as an active ingredient by the method for screening a substance having a high affinity with the target substance of the present invention.
  • the design of molecular targeted drugs it is possible to eliminate the elucidation of the cause of the disease at the molecular level or genome level by simplifying the selection of the compound library, and to simplify the molecular design of the drug. Improvement can be expected.
  • a drug can be produced using the selected candidate substance as an active ingredient by the method for screening a substance having a high affinity for the target substance of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La présente invention concerne un procédé d'analyse d'une substance ayant une haute affinité pour une substance cible qui consiste : en une étape de préparation d'un échantillon de mesure dans lequel un échantillon contenant une substance candidate est mis en contact avec la substance cible ; en une étape lors de laquelle l'échantillon de mesure est soumis à une spectrométrie de masse par imagerie par désorption/ionisation au laser assistée par matrice (MALDI) avec la substance cible en tant que matrice, pour identifier une molécule ionisée ; et en une étape de sélection de la molécule identifiée en tant que substance ayant une haute affinité pour la substance cible.
PCT/JP2018/003442 2017-02-01 2018-02-01 Procédé d'analyse de substance ayant une haute affinité pour une substance cible WO2018143357A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018566091A JPWO2018143357A1 (ja) 2017-02-01 2018-02-01 標的物質と親和性の高い物質をスクリーニングする方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017016609 2017-02-01
JP2017-016609 2017-02-01

Publications (1)

Publication Number Publication Date
WO2018143357A1 true WO2018143357A1 (fr) 2018-08-09

Family

ID=63040711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/003442 WO2018143357A1 (fr) 2017-02-01 2018-02-01 Procédé d'analyse de substance ayant une haute affinité pour une substance cible

Country Status (2)

Country Link
JP (1) JPWO2018143357A1 (fr)
WO (1) WO2018143357A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003248001A (ja) * 2002-02-22 2003-09-05 Inst Of Physical & Chemical Res リガンドとの分子間相互作用を有するタンパク質のスクリーニング方法
JP2007170870A (ja) * 2005-12-19 2007-07-05 Protosera Inc 質量分析を用いたｉｎｓｉｔｕ検出方法
JP2008111841A (ja) * 2003-01-16 2008-05-15 Hubert Koester 捕獲化合物、その収集物ならびにプロテオームおよび複合組成物を分析するための方法
JP2008542784A (ja) * 2005-06-07 2008-11-27 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） 組織切片のｍａｌｄｉ質量分析法による分析のためのイオンマトリックスの使用
JP2014206389A (ja) * 2013-04-10 2014-10-30 独立行政法人国立がん研究センター 質量分析用試料調整方法及び質量分析方法
JP2015155884A (ja) * 2014-01-17 2015-08-27 国立研究開発法人産業技術総合研究所 Ｍａｌｄｉ質量分析用界面活性型マトリックス
JP2016511402A (ja) * 2013-02-25 2016-04-14 イマビオテクＩｍａｂｉｏｔｅｃｈ 目的の分子の組織ターゲティングを評価するための方法
JP2016080531A (ja) * 2014-10-17 2016-05-16 国立研究開発法人国立長寿医療研究センター 微小生体組織片の作製装置、作製方法、及び化合物のスクリーニング方法
JP2016121968A (ja) * 2014-12-25 2016-07-07 シチズンファインデバイス株式会社 試料積載プレート

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003248001A (ja) * 2002-02-22 2003-09-05 Inst Of Physical & Chemical Res リガンドとの分子間相互作用を有するタンパク質のスクリーニング方法
JP2008111841A (ja) * 2003-01-16 2008-05-15 Hubert Koester 捕獲化合物、その収集物ならびにプロテオームおよび複合組成物を分析するための方法
JP2008542784A (ja) * 2005-06-07 2008-11-27 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） 組織切片のｍａｌｄｉ質量分析法による分析のためのイオンマトリックスの使用
JP2007170870A (ja) * 2005-12-19 2007-07-05 Protosera Inc 質量分析を用いたｉｎｓｉｔｕ検出方法
JP2016511402A (ja) * 2013-02-25 2016-04-14 イマビオテクＩｍａｂｉｏｔｅｃｈ 目的の分子の組織ターゲティングを評価するための方法
JP2014206389A (ja) * 2013-04-10 2014-10-30 独立行政法人国立がん研究センター 質量分析用試料調整方法及び質量分析方法
JP2015155884A (ja) * 2014-01-17 2015-08-27 国立研究開発法人産業技術総合研究所 Ｍａｌｄｉ質量分析用界面活性型マトリックス
JP2016080531A (ja) * 2014-10-17 2016-05-16 国立研究開発法人国立長寿医療研究センター 微小生体組織片の作製装置、作製方法、及び化合物のスクリーニング方法
JP2016121968A (ja) * 2014-12-25 2016-07-07 シチズンファインデバイス株式会社 試料積載プレート

Also Published As

Publication number Publication date
JPWO2018143357A1 (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
Cupp-Sutton et al. High-throughput quantitative top-down proteomics
Bodzon‐Kulakowska et al. Imaging mass spectrometry: instrumentation, applications, and combination with other visualization techniques
Seeley et al. Imaging of intact tissue sections: moving beyond the microscope
Mallah et al. Lipid changes associated with traumatic brain injury revealed by 3D MALDI-MSI
Kim et al. Understanding metabolomics in biomedical research
Lanekoff et al. Shotgun approach for quantitative imaging of phospholipids using nanospray desorption electrospray ionization mass spectrometry
Wang et al. Hydroxyflavones as a new family of matrices for MALDI tissue imaging
Nemes et al. Simultaneous imaging of small metabolites and lipids in rat brain tissues at atmospheric pressure by laser ablation electrospray ionization mass spectrometry
Monroe et al. SIMS and MALDI MS imaging of the spinal cord
KR100967573B1 (ko) 대사산물 프로파일의 정량 분석용 기구
EP3306310B1 (fr) Procédé de quantification d'anticorps monoclonal
Sugiura et al. Visualization of acetylcholine distribution in central nervous system tissue sections by tandem imaging mass spectrometry
Rao et al. High-resolution ambient MS imaging of negative ions in positive ion mode: using dicationic reagents with the single-probe
Franck et al. Quantification-based mass spectrometry imaging of proteins by parafilm assisted microdissection
Anderton et al. Identification of a lipid‐related peak set to enhance the interpretation of TOF‐SIMS data from model and cellular membranes
Ait-Belkacem et al. Mass spectrometry imaging is moving toward drug protein co-localization
Karlsson et al. Quality measures of imaging mass spectrometry aids in revealing long-term striatal protein changes induced by neonatal exposure to the cyanobacterial toxin β-N-methylamino-l-alanine (BMAA)
Prentice et al. Label-free molecular imaging of the kidney
Burton et al. Enriching extracellular vesicles for mass spectrometry
Chen et al. Imaging of neurotransmitters and small molecules in brain tissues using laser desorption/ionization mass spectrometry assisted with zinc oxide nanoparticles
Jiang et al. Innovation in drug toxicology: Application of mass spectrometry imaging technology
Quanico et al. Integrated mass spectrometry imaging and omics workflows on the same tissue section using grid-aided, parafilm-assisted microdissection
Ferguson et al. Mass spectrometry-based tissue imaging of small molecules
Gao et al. Mass spectrometry imaging technology in metabolomics: a systematic review
Lee et al. In vitro tracking of intracellular metabolism-derived cancer volatiles via isotope labeling

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18748064

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018566091

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18748064

Country of ref document: EP

Kind code of ref document: A1